Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $153.00 | Strong Buy | Raymond James |
| 8/14/2024 | $180.00 | Outperform | William Blair |
| 3/28/2024 | $100.00 → $115.00 | Buy | H.C. Wainwright |
| 2/27/2024 | $120.00 | Outperform | BMO Capital Markets |
| 12/4/2023 | $100.00 | Buy | H.C. Wainwright |
| 11/29/2023 | $70.00 | Outperform | RBC Capital Mkts |
| 11/10/2023 | $180.00 | Overweight | Piper Sandler |
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened balance sheet with closing of $70.0 million private placement (PIPE) on April 22, 2024, with cash and cash equivalents of approximately $206 million at close Cash runway into second half of 2026 to fund anticipated interim readout of KRRO-110 in the second half of 2025 and FIH study completion in 2026 Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company
Raymond James initiated coverage of Korro Bio with a rating of Strong Buy and set a new price target of $153.00
William Blair initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $180.00
H.C. Wainwright reiterated coverage of Korro Bio with a rating of Buy and set a new price target of $115.00 from $100.00 previously
424B3 - Korro Bio, Inc. (0001703647) (Filer)
424B3 - Korro Bio, Inc. (0001703647) (Filer)
8-K - Korro Bio, Inc. (0001703647) (Filer)
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conferenc
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026 CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that it has received approval from the Australian Bellberry Human Research Ethics Committee (HREC) and clearance from the A
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro's website a
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $100 price target.
KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model KRRO-110 showed 35µM of M-AAT one week post the first dose, with 0µM of M-AAT at baseline, increasing to 45µM of M-AAT at week 13
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)